Anzeige
Mehr »
Login
Montag, 18.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Solarbetriebene Krypto-Strategie lässt Aktie an einem Tag um 100% steigen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
246 Leser
Artikel bewerten:
(1)

Bened Biomedical: Psychobiotic PS128 Improves Mood and Sleep Quality in Its First Clinical Study on Anxiety and Stress

Finanznachrichten News

TAIPEI, TAIWAN / ACCESSWIRE / April 13, 2021 / Bened Biomedical's psychobiotic PS128 significantly improved insomnia, stress, and anxiety during a recent clinical trial. Participants were tech industry professionals under high levels of work-life stress.

Psychobiotics are probiotics which yield specific mental health benefits. PS128, a strain of probiotic Lactobacillus plantarum, has previously shown improvements to signs of anxiety and stress in preclinical models. This study attempted to see if taking PS128 would similarly benefit human health.

Front: National Yang-Ming University's Professor Ying-Chieh Tsai, who leads Bened's psychobiotic research team. The team's latest clinical trial shows improvements of anxiety, stress, and sleep quality from taking PS128. (Photo via Bened Biomedical)

The psychobiotic was found to benefit anxiety, stress, and sleep quality. The findings of the trial were published this March in Frontiers in Nutrition. (https://doi.org/10.3389/fnut.2021.614105)

"We know life is and will continue to be just as busy and stressful as ever. Seeing that PS128 can help people sleep better at night and put them in a better mood each day makes us glad to be able to provide this kind of product," said Dr. Alain Delpy, head of global development at Bened.

PS128 shows perceived mental and physical health benefits

In the study, 36 individuals took PS128 daily for eight weeks. Comparing their responses at the beginning and end of the trial, many measures changed significantly. Participants reported higher levels of energy and positive emotions, as well as better quality of life and psychological health. Improvements were seen in measures of insomnia severity, anxiety, job stress, negative emotions, and gastrointestinal symptoms.

"We are very pleased to see these results in people, to verify what we have already seen in preclinical experiments. PS128 really can benefit the high-pressure, high-stress, high-anxiety world we live and work in," Delpy said.

Probiotics can impact health through a pathway called the gut-brain axis. One theory is that PS128 interacts within the gut, and molecules that are then released travel via the bloodstream or nerves directly to the brain. Previous studies have shown that rodents given PS128 had higher levels of serotonin and dopamine in their brains, and boosted amounts of these neurotransmitters could correlate with the benefits seen in this trial.

PS128 intervention reduces stress hormone cortisol

In addition to recording how participants felt, the study tested samples of their saliva for key stress biomarkers. Levels of one of these, cortisol, dropped significantly during the trial.

"Seeing reduced cortisol levels is probably the most important takeaway from this experiment," said Dr. Allen Wu, who heads Bened's research lab. "It proves that PS128 is causing real changes in the body, changes which can then be experienced and felt by the mind."

All-natural, vegan PS128 has self-affirmed GRAS status. Previous clinical trials have shown that higher doses of the psychobiotic may alleviate symptoms of other neurological conditions such as Parkinson's, autism, and depression.

Actively advancing gut-brain axis research, Bened is a worldwide ODM looking for new partners to extend PS128's availably in markets around the globe.

About Bened Biomedical

Founded in 2015 in Taipei, Taiwan, Bened Biomedical Co., Ltd. is a global leader of microbiome-based products. The company focuses on therapy for neuropsychological, aging-related, allergic, immunological, and metabolic disorders. Bened aims to develop functional probiotic strains and live biotherapeutic products that can alter human microbiome to prevent and treat diseases. The name "Bened," derived from the Latin word for "full of blessings," affirms the brand's hope to bless the world through its products.

For more information: https://www.benedbiomed.com/

The published trial: https://doi.org/10.3389/fnut.2021.614105

Contacts:

Bened Biomedical Co., Ltd.
Dr. Alain Delpy
+886-2-2511-1122
alain.delpy@benedbiomed.com

SOURCE: Bened Biomedical



View source version on accesswire.com:
https://www.accesswire.com/640106/Psychobiotic-PS128-Improves-Mood-and-Sleep-Quality-in-Its-First-Clinical-Study-on-Anxiety-and-Stress

© 2021 ACCESSWIRE
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.